Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03932240 · ClinicalTrials.gov registry record · Phase 3
In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)
A Phase 3 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 3
- Development phase
- 36
- Enrollment target
NCT03932240 is a Phase 3 study that has completed, run by Emory University. The registered enrollment target is 36 participants.
The verdict
NCT03932240, a Phase 3 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 36 participants
- Enrollment target
Study Summary
This primary aim of this study is to compare the in vivo effects of fibrinogen concentrate and cryoprecipitate on the neonatal fibrin network after surgery with cardiopulmonary bypass to develop effective and safe strategies for managing coagulopathies in neonates.
Interventions
- DRUG Cryoprecipitate
- DRUG Fibrinogen Concentrate (FC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-08-13 |
| Est. Completion | 2021-11-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03932240
The ClinicalTrials.gov registry entry for NCT03932240 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cryoprecipitate is the first listed.
NCT03932240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03932240 about?
NCT03932240 is a clinical study titled "In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)". This primary aim of this study is to compare the in vivo effects of fibrinogen concentrate and cryoprecipitate on the neonatal fibrin network after surgery with cardiopulmonary bypass to develop effective and safe strategies for managing coagulopathies in neonates.
What is the current status of trial NCT03932240?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2019-08-13. Estimated completion is 2021-11-16.
What interventions are being tested in trial NCT03932240?
The interventions under investigation include: Cryoprecipitate (DRUG), Fibrinogen Concentrate (FC) (DRUG).
Who is sponsoring clinical trial NCT03932240?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.